Please assess the completion status of the following clinical trial:

Trial Title: Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At least 18 years of age at the time of study entry~* Histologically confirmed metastatic and/or unresectable GIST with prior failure of both conventional tyrosine kinase inhibitors, imatinib and sunitinib.~* Measurable disease per RECIST 1.1. A lesion in a previously irradiated area is eligible to be considered as measurable disease as long as there is objective evidence of progression of the lesion.~* ECOG Performance Status 0 or 1~* Adequate organ and marrow function as outlined in the protocol~* Fully recovered from the acute effects of prior cancer therapy before initiation of study drug~* Patients must be suitable for oral drug administration~* Willingness to use effective means of birth control throughout the duration of clinical study and for at least 3 months after completion of study drug~* Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of study drug administration~Exclusion Criteria:~* Use of any unapproved tyrosine kinase inhibitors or investigational agents within 2 weeks or 6 half-lives of the agent, whichever is shorter, prior to receiving study drug~* Participants who have had radiotherapy within 4 weeks prior to study entry~* Major surgery, or significant traumatic injury within 4 weeks prior to study entry~* Presence of symptomatic or uncontrolled brain or central nervous system metastases~* Prior exposure to sorafenib~* Prior exposure to regorafenib~* Known or suspected allergy to the investigational agent or any agent given in association with this trial~* Individuals with a history of a different malignancy, other than cervical cancer in situ, basal cell or squamous cell carcinoma of the skin, are ineligible, except if they have been disease-free for at least 5 years, and are deemed by the investigator to be at low risk for recurrence of that malignancy or other primary malignancy is neither currently clinically significant nor requiring active intervention~* Clinically significant cardiac arrhythmias and/or patients who require anti-arrhythmic therapy (excluding beta blockers or digoxin)~* History of clinically significant cardiac disease or congestive heart failure \> NYHA class 2. Patients must not have unstable angina or new-onset angina within the last 3 months or myocardial infarction within the past 6 months~* Hypertension as defined by systolic blood pressure 140-159 mmHg or diastolic blood pressure 90-99 mmHg; recurrent or persistent or symptomatic increase by \> 20 mmHg (diastolic) or to systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg if previously within normal limits, despite optimal medical management~* Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within the 6 months before start of study medication~* Ongoing infection of Grade 3 or higher~* Patients with evidence of, or history of, bleeding diathesis. Any major hemorrhage or bleeding event of Grade 3 or higher within 4 weeks of start of study medication~* Non-healing wound, ulcer or bone fracture~* Renal failure requiring hemo-or peritoneal dialysis~* Dehydration of Grade 2 or greater~* Persistent proteinuria Grade 3 or higher~* Known history of HIV infection or chronic hepatitis B or C~* Uncontrolled intercurrent illness~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regorafenib (Type: EXPERIMENTAL): Regorafenib adminstered orally, 160 mg per day on days 1 through 21 of a 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).